Arrowhead Pharmaceuticals, Inc. (NasdaqGS: ARWR)
Health Care · Biotechnology · US
$60.85
-3.04% today · +74.0% 1Y
Arrowhead Pharmaceuticals, Inc. (NasdaqGS: ARWR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $8.86B and employs 711 people.
Over the last twelve months the share price has gained 74.0%, trading between 34.61 and 95.49.
Tweenvest scores Arrowhead Pharmaceuticals, Inc. across four factors: quality 36/100, value 54/100, growth 100/100. Its strongest factor is growth.
ARWR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.86B
- Revenue (TTM)
- $669.50M
- P/E
- —
- EPS
- -2.28
- Dividend yield
- —
- Beta (5Y)
- 1.30
- 52-week high
- $95.49
- 52-week low
- $34.61
- Avg volume (3M)
- —
- Shares outstanding
- 141.25M
- Employees
- 711
- Next earnings
- —
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
- ISIN
- US04280A1007
- Founded
- 2003
- Listed since
- Dec 16, 1993
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Twist Bioscience CorporationNasdaqGS: TWST | $10.02B | $150.74 | -5.66% |
| Krystal Biotech, Inc.NasdaqGS: KRYS | $9.82B | $331.71 | +0.03% |
| Kymera Therapeutics, Inc.NasdaqGM: KYMR | $9.35B | $110.87 | -1.36% |
| Protagonist Therapeutics, Inc.NasdaqGM: PTGX | $9.30B | $144.79 | +0.74% |
| Cytokinetics, IncorporatedNasdaqGS: CYTK | $8.75B | $63.06 | +0.24% |
| Caris Life Sciences, Inc.NasdaqGS: CAI | $8.39B | $29.02 | -2.29% |
| Spyre Therapeutics, Inc.NasdaqGS: SYRE | $8.01B | $85.66 | -0.04% |
| TG Therapeutics, Inc.NasdaqCM: TGTX | $7.85B | $55.67 | +0.54% |
Figures last refreshed Oct 11, 2026.